Navigation Links
AtheroNova Announces Approval for Phase 1 by the Russian Ministry of Healthcare with Commencement of Human Trials Imminent
Date:5/9/2013

tiation of human clinical trials, potentially addressing one of the major health risks facing both Russia and the rest of the world," remarked Andrey Boldyrev , General Director of CardioNova. "We are currently working with the CRO and the trial centers to distribute the approved protocol and making final preparations for the initiation of pre-screening and ultimately Phase 1 clinical trials in our Russian study centers."

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain pharmacological compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are then removed by natural body processes. AtheroNova is developing, and seeks to eventually market AHRO-001, a product that has the potential to become a new standard of care for patients prone to atherosclerotic plaque accumulation.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a biotechnology company focused on the discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits and to safely improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patents-pending therapies in market sectors that include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone. For more information, please
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. AtheroNova Announces a New Board Member
4. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
5. AtheroNova Releases 2011 Financial Results
6. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
7. AtheroNova Names New Director
8. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
9. AtheroNova Adds New Medical Advisor
10. Noted Atherosclerosis Researcher Joins AtheroNova Team
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Bioptigen announced today the availability of ... optical device metrology and pre-clinical ophthalmic research markets. ... Contact Lens Metrology is designed for non-destructive, non-contact, full ... IOL structures, and donor tissues. The metrology ... in a hydration bath (saline), automated segmentation of anterior ...
(Date:9/15/2014)... AUSTIN, Texas , Sept. 15, 2014 The ... changes in climate, says a new article published by the ... Ahmed , PhD, on climate change and its effects on ... part of an extensive study conducted by Dr. Ahmed in ... China and has implications for the future ...
(Date:9/15/2014)... Maryland , 15 de septiembre de 2014 ... se llevará a cabo del 12 al 18 de octubre. ... (PPTA) y de sus compañías miembro s, la ... la concienciación mundial en torno a la colección de fuentes ... donantes de plasma al salvar y mejorar las vidas ...
(Date:9/14/2014)... variety of ways, including by modifying the protein structure. ... form and perform no or even the "wrong" function: ... diseases such as Alzheimer,s, Parkinson,s or cystic fibrosis. Some ... other molecules of the same type and congregate into ... damage cells and tissues and make people ill. , ...
Breaking Biology Technology:Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3Measuring modified protein structures 2Measuring modified protein structures 3
... material that could become essential to efficient, environmentally ... advantage of graphene,s outstanding strength, light weight and ... wells. The Rice University lab of chemist ... Texas-based supplier of drilling fluids and subsidiary of ...
...  Kensey Nash Corporation (Nasdaq: KNSY ) today ... (Nasdaq: SPNC ) that they reached a ... product lines purchased from Kensey Nash in May 2008. ... payable to Kensey Nash.  As previously disclosed, the Company ...
... Sangui enters commercialization phase / Initial order of ... Tamaulipas has issued an initial order of Hemo2Spray, the Sangui ... product Scabremove both registered by the Mexican authorities in September ... the wound spray and Sangui management is positive that an ...
Cached Biology Technology:Functionalized graphene oxide plays part in next-generation oil-well drilling fluids 2Functionalized graphene oxide plays part in next-generation oil-well drilling fluids 3Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management 2
(Date:9/16/2014)... years after the Hesperides vessel returned to Spain culminating ... have an increasingly clear picture of how the global ... the input of pollutants from the atmosphere is not ... most remote areas of the planet, and it is ... are presented this week in CSIC Residence for Researchers ...
(Date:9/16/2014)... . CRG researchers ... Journal of Cell Biology describes how Topo 2 ... , At this very moment thousands of our body,s cells ... the body repairs damaged tissues and regenerates others like skin ... "mitosis", during which the cell duplicates its genetic material and ...
(Date:9/16/2014)... Sept. 16, 2014  Cross Match Technologies, a ... announced today the launch of its Verifier ® ... identity of an individual using their secure credentials ... rapidly reads credential documents with embedded biometric data ... the biometric to a live scan of their ...
Breaking Biology News(10 mins):The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3Unraveling cell division 2Unraveling cell division 3Cross Match Launches New Identity Management Handheld Solution 2
... ROCKVILLE, Md. -- Several members of the American Society ... or foreign associates of the U.S. National Academy of ... in original research. Three current ASPB members were ... Birchler , Curators Professor of Biological Sciences, University of ...
... Callaghan, a researcher at the Royal Swedish Academy of Sciences, ... and permafrost. "The changes we see are dramatic. ... deviate from the norm when compared with a longer term ... parts of the globe that is warming up fastest today. ...
... and Shinya Yamanaka, MD, PhD, have been elected as members ... in original scientific research. It is one of the highest ... States. They join 70 other scientists who will ... now has 40 current faculty members in the distinguished group. ...
Cached Biology News:A new research report shows effects of climate change in the Arctic are more extensive than expected 2A new research report shows effects of climate change in the Arctic are more extensive than expected 3UCSF scientists honored by National Academy of Sciences 2